Activity of low-grade systemic inflammation in patients with resistant arterial hypertension

Main Article Content

L. A. Mishchenko
O. O. Matova
M. Yu. Sheremet
K. I. Serbeniuk
O. B. Kuchmenko

Abstract

The aim – to study the activity of low-grade inflammation and determine an interaction of its parameters with characteristics of humoral systems of blood pressure regulation, hypertensive heart and kidney damage in patients with resistant arterial hypertension (AH).
Material and methods. The results of examination of 129 patients with AH (72 patients with controlled AH, 57 persons with resistant AH) were included into the analysis. All patients, besides routine clinical examination, underwent 24-hours’ blood pressure monitoring, evaluation of systemiс inflammation markers (C-reactive protein, fibrinogen, IL-6, TNF-α), MMP-12 activity, cystatin C, renin, aldosterone, citrulline blood concentration; 24-hours’ excretion of albumin and metanephrine.
Results. In the resistant AH, compared to the patients with controlled arterial hypertension, higher levels of inflammation active phase proteins (C-reactive proteins – by 17.3 %, fibrinogen – by 10.6 %) and proinflammatory cytokines (IL-6 by 21.8 % TNF-α by 13 %) were detected. The activation of low-grade inflammation in patients with resistant AH has been associated with higher renin-angiotensin-aldosterone system activity: the concentration of plasma aldosterone correlated with IL-6 level (r=0.334; Р=0.03) and matrix metalloproteinase 12 activity (r=0.326; Р=0.02); active renin blood contents – with IL-6 (r=0.416; Р=0.01) and TNF-α (r=0.323; Р=0.03) levels). In patients with resistant AH the increase of left ventricle myocardial mass index was accompanied by elevation of plasma IL-6, and decrease of glomerular filtration rate was associated with growth of plasma TNF-α blood level (r=0.318; Р=0.04). Correlation of
MMP-12 activity with renal impairment markers – cystatin С (r=0.405; Р=0.01) and citrulline (r=0.338; Р=0.03) was detected. In resistant AH pts increase of LVMI was accompanied by elevation of IL-6.
Conclusions. Resistant AH was characterized by more expressed activation of low – grade inflammation, compared to controlled AH, which is associated with renin-angiotensin-aldosterone system activation and hypertensive injury of heart and kidneys.

Article Details

Keywords:

Resistant arterial hypertension, low-grade inflammation, C-reactive protein, cytokines, cystatin C, glomerular filtration rate.

References

Mishchenko LA. Rol netraditsiynih chinnikiv sertsevo-sudinnogo riziku v patogenezi gipertonichnoyi hvorobi. Ukrayinskiy kardiologichniy zhurnal. -The state of nontraditional cardiovascular risk factors in pathogenesis of essential hypertension. Ukrainskyi kardiolohichnyi zhurnal [Ukrainian Journal of Cardiology] 2012;3:15–21. (in Ukr.). http://journal.ukrcardio.org/wp-content/uploads/2012/03/1_3_2012.pdf

Mkhіtarian LS, Kuchmenko OB, ЄvstratovaІN, Lіpkan NG, Vasilinchuk NM, Drobot`ko TF. Tcitrulіn iak marker funktcіonal`nogo stanu organіv za umov patologіchnikh stanіv – Citrullineas a marker of organs functional state in conditions of pathology. Ukrainskyi kardiolohichnyi zhurnal [Ukrainian Journal of Cardiology] 2016;3:109–115(in Ukr.). http://www.ucardioj.com.ua/index.php/UJC/issue/view/19/ujc%203%2016

Barbaro NR, Fontana V, Modolo R, De Faria AP, Sabbatini AR, FonsecaFH, Anhe GF, Moreno H. Increased arterial stiffness in resistant hypertension is associated with inflammatory biomarkers. Blood Press 2015;24:7–13. https://www.ncbi.nlm.nih.gov/pubmed/25061978

Bautista LE, Vera LM, Arenas IA, Gamarra G. Independent association between inflammatory markers (C-reactive protein, interleikin-6 and TNF-alfa) and essential hypertension. J. Human hypertens 2005;19:149–154.

Boos CJ, Lip GN. Is hypertension an inflammatory process? Cur Pharm Des 2006;12:1623–1635. http://doi.org/10.1016/10.1038/sj.jhh.1001785

Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension2002;40(6):892–896. https://www.ncbi.nlm.nih.gov/pubmed/12468575

Cheung BM, Ong KL, Tso AW, Leung RY, Xu A, Cherny SS, Sham PC, Lam TH, Lam KS. C-reactive protein as a predictor of hypertension in the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS) cohort. J. Hum. Hypertens2012;26(2):108–116. http://doi.org/10.1038/jhh.2010.125

Cortez AF, Muxfeldt ES, Cardoso CR, Salles GF. Prognostic value of C-reactive protein in resistant hypertension. Am. J. Hypertens. 2016;29(8):992–1000. http://doi.org/10.1093/ajh/hpw011

Dauphine V, Roche F, Kossovsky MP. C-reactive protein protein implication in new onset hypertension in a healthy population initially aged 65 years: PROOF study. J. Hypertens. 2009;27:736–743. http://doi.org/10.1097/HJH.0b013e328326f801

de Souza F, Muxfeldt ES, Salles GF. Prognostic factors in resistant hypertension: implications for cardiovascular risk stratification and therapeutic management. Expert Rev. Cardiovasc. Ther. 2012;10:735–745. http://doi.org/10.1586/erc.12.58

Duprez DA. Aldosterone and the vasculature: mechanisms mediating resistant hypertension. J. Clin. Hypertens. (Greenwich).2007;9(Suppl 1):13–18. https://www.ncbi.nlm.nih.gov/pubmed/17215650

Niu H, Li Y, Li H, Chi Y, Zhuang M, Zhang T, Liu M, Nie L. Matrix metalloproteinase 12 modulates high-fat-diet induced glomerular fibrogenesis and inflammation in a mouse model of obesity. Scientific Reports. – Published online 2016 Jan 29. doi: http://doi.org/10.1038/srep20171.

Iyer RP, Patterson NL, Zouein FA, Ma Y, Dive V, de Castro Brás LE, Lindsey ML. Early matrix metalloproteinase-12 inhibition worsens post-myocardial infarction cardiac dysfunction by delaying inflammation resolution. Int J Cardiol.2015.Vol.15(185).P.198-208. doi: http://doi.org/10.1016/j.ijcard.2015.03.054. Epub 2015 Mar 5.

Kasal DB, Schiffrin EL. Angiotensin II, aldosterone, and anti-inflammatory lymphocytes: interplay and therapeutic opportunities. Intern J Hypertens2012;ID 829786. http://doi.org/10.1155/2012/829786

KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplement 2013;3:1–150. http://doi.org/10.1038/ki.2013.243.

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2015;16(3):233–270. http://doi.org/10.1016/j.echo.2014.10.003.

Magen E, Mishal J, Paskin J, Glick Z, Yosefy C, Kidon M, Schlesinger M. Resistant arterial hypertension is associated with higher blood levels ofcomplement C3 and C-reactive protein. J Clin Hypertens (Greenwich)2008;10:677–683. http://doi.org/10.1111/j.1751-7176.2008.00002.x.

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281–1357. http://doi.org/10.1097/01.hjh.0000431740.32696.cc.

Niu H, Li Y, Li H, Chi Y, Zhuang M, Zhang T, Liu M, Nie L. Matrix metalloproteinase 12 modulates high-fat-diet induced glomerular fibrogenesis and inflammation in a mouse model of obesity. Scientific Reports2016;6:20171. http://doi.org/10.1038/srep20171.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195–207. http://doi.org/10.1056/NEJMoa0807646.

Ridker PM, Everett BM, Thuren T. Antiinflammatory therapy with canakinumab for atherosclerotic disease. J.G. N Engl J Med 2017;377:1119–1131. http://doi.org/10.1056/NEJMoa1707914.

Ridker PM, Morrow DA, Rose LM, Rifai N, Cannon CP, Braunwald E. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. J Am. Coll. Cardiol. 2005;45:1644–1648. http://doi.org/10.1016/j.jacc.2005.02.080

Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 2007;49:2129–2138. http://doi.org/10.1016/j.jacc.2007.02.052

Salles GF, Fiszman R, Cardoso CR, Muxfeldt ES. Relation of left ventricular hypertrophy with systemic inflammation and endothelial damage in resistant hypertension. Hypertension 2007;50:723–728. http://doi.org/10.1161/HYPERTENSIONAHA.107.093120

Sesso HD, Wang L, Buring JE, Ridker PM, Gaziano JM. Comparison of inerleikin-6 and C-reactive protein for the risk of developing hypertension in women. Hypertension 2007;49:304–310. http://doi.org/10.1161/01.HYP.0000252664.24294.ff

Wang Y, Ait-Oufella H, Herbin O, Bonnin P, Ramkhelawon B, Taleb S, Huang J, Offenstadt G, Combadiore C, Ronia L, Johnson JL, Tharaux PL, Tedgui A, Mallat Z. TGF-beta activity protects against inflammatory aortic aneurysm progression and complications in angiotensin II infused mice. J Clin Invest 2010;120(2):422–432. http://doi.org/10.1172/JCI38136

Most read articles by the same author(s)